Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
about
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- miceShould endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Advances in chemical pharmacotherapy to manage advanced breast cancer.New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Update Breast Cancer 2017 - Implementation of Novel Therapies.Antiangiogenic therapy in breast cancer.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway.Progress in targeted therapy for breast cancer
P2860
Q31157714-D98D5CB3-D10F-48F5-BE58-CF46AF8A5330Q33656801-CE94AF36-9E4B-4423-B5E8-F7BCB5E5414BQ33799297-0E877CC3-E122-44A0-8ED4-8B1F75EC3268Q38661501-4475BF31-E557-4E3B-8B8C-DD7F1A0F8A76Q38662999-89B068E0-4491-40BB-A9CD-C73CEFAC00E2Q38683638-D580FD3D-1A47-42CF-AE46-BE4B00D0AA4AQ38786066-3A35A98F-37B0-4191-9F75-A3DBBCF61B67Q38809459-F31F277F-B65D-481C-8511-457D79683133Q38870640-B4E809E7-F2C7-4482-A9C9-969AD434DAC8Q39089103-1CD324DE-5BA3-4F42-BC54-5249D0F84679Q39172983-49F6C5C9-B454-4480-BEBD-475CDDE6FDF7Q39402106-7509B0A9-40D1-4D71-BABF-3EC39A85E112Q41346466-6E9FEA3C-ADF1-43E9-9D2A-64B72150E089Q46537162-8ADB1E5E-80C4-44D9-8262-5B4CE4617B74Q47110841-664B52F0-74E0-41AF-8AF3-F3AD08D10B8AQ47111400-8D326905-0AE0-4850-8F05-37BDD15E5B39Q47561979-5E542A5A-C847-4A38-9513-E74F22F12E03Q50114923-6427EC17-A9C1-40DF-81F8-0254E0E771D1Q50419857-D6C7D0D1-363C-4352-9E4E-BEF487F0B26FQ54957190-72CE4EA5-C220-41EE-8DD5-E886D571C45AQ54978022-FAD1C3C5-23E0-40A2-8457-F473A8FE09FFQ57109788-4BD41DAB-556C-4648-9AF2-126CC355DD96
P2860
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)
@en
Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503
@nl
type
label
Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)
@en
Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503
@nl
prefLabel
Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)
@en
Phase III Trial Evaluating Let ...... age Breast Cancer: CALGB 40503
@nl
P2093
P2860
P356
P1476
Phase III Trial Evaluating Let ...... Cancer: CALGB 40503 (Alliance)
@en
P2093
Arti Hurria
Bryan P Schneider
Clifford A Hudis
Constance T Cirrincione
Debasish Tripathy
Diana E Lake
Eric P Winer
Federico Innocenti
Hope S Rugo
Lisa A Carey
P2860
P304
P356
10.1200/JCO.2015.66.1595
P407
P577
2016-05-02T00:00:00Z